Fig. 2From: Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxisThe progression-free survial (PFS) curves of patients with baseline HBV DNA level ≤ 2000 IU/mL and those with DNA level > 2000 IU/mL receiving anti-PD-1 in combination with antiangiogenic therapyBack to article page